Phase I study of the irreversible fibroblast growth factor receptor 1–4 inhibitor futibatinib in Japanese patients with advanced solid tumors-Reference-Cited by-同舟云学术

Phase I study of the irreversible fibroblast growth factor receptor 1–4 inhibitor futibatinib in Japanese patients with advanced solid tumors

Published:2022-12-04 Issue:2 Volume:114 Page:574-585
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Science

Author:

Doi Toshihiko¹^ORCID,Shitara Kohei²^ORCID,Kojima Takashi³^ORCID,Kuboki Yasutoshi¹,Matsubara Nobuaki⁴^ORCID,Bando Hideaki³^ORCID,Yoh Kiyotaka⁵^ORCID,Naito Yoichi¹⁴⁶^ORCID,Hirai Hiroshi⁷,Kurokawa Yukinori⁸,Kato Terufumi⁹,Morizane Chigusa¹⁰

Affiliation:

1. Department of Experimental Therapeutics National Cancer Center Hospital East Kashiwa Japan

2. Department of Gastrointestinal Oncology National Cancer Center Hospital East Kashiwa Japan

3. Department of Gastroenterology and Gastrointestinal Oncology National Cancer Center Hospital East Kashiwa Japan

4. Department of Medical Oncology National Cancer Center Hospital East Kashiwa Japan

5. Department of Thoracic Oncology National Cancer Center Hospital East Kashiwa Japan

6. Department of General Internal Medicine National Cancer Center Hospital East Kashiwa Japan

7. Discovery and Preclinical Research Division Taiho Pharmaceutical Co., Ltd. Tsukuba Japan

8. Department of Gastroenterological Surgery Osaka University Graduate School of Medicine Osaka Japan

9. Department of Thoracic Oncology Kanagawa Cancer Center Yokohama Japan

10. Department of Hepatobiliary and Pancreatic Oncology National Cancer Center Hospital Tokyo Japan

Funder

Taiho Pharmaceutical

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.15486

Reference36 articles.

1. FGF/FGFR signaling in health and disease

2. Role of the fibroblast growth factor receptor axis in cholangiocarcinoma

3. Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma

4. Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer

5. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups;Courjal F;Cancer Res,1997

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase I drug–drug interaction study to assess the effect of futibatinib on P‐gp and BCRP substrates and of P‐gp inhibition on the pharmacokinetics of futibatinib;Clinical and Translational Science;2024-09

2. Exploring the Horizon: Anti-Fibroblast Growth Factor Receptor Therapy in Pancreatic Cancer with Aberrant Fibroblast Growth Factor Receptor Expression—A Scoping Review;Cancers;2024-08-22

3. Emerging Therapeutic Targets and Future Directions in Advanced Gastric Cancer: A Comprehensive Review;Cancers;2024-07-29

4. State-of-the-art and trends in fibroblast growth factor receptor-directed therapies in gastro-intestinal malignancies;Current Opinion in Oncology;2024-05-07

5. Futibatinib: A Review in Locally Advanced and Metastatic Cholangiocarcinoma;Targeted Oncology;2024-05